These results postulate that supplemental ASTX ameliorates hyperglycemia-associated systemic complications by upregulating the Nrf2 and Nrf2-dependent antioxidant system, as well as by recovering an impaired hematopoietic development. The gene discussed is NFE2L2; the disease is Hyperglycemia.